Intelligent Bio Solutions Inc. (INBS) Financial Statements (2025 and earlier)
Company Profile
Business Address |
135 W 41ST ST, NEW YORK, NY 10036 |
State of Incorp. | DE |
Fiscal Year End | June 30 |
Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
12/31/2024 MRQ | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |||
---|---|---|---|---|---|---|---|
ASSETS | |||||||
Current Assets | |||||||
Cash, cash equivalents, and short-term investments | 6,304 | 1,537 | 8,238 | 12,574 | |||
Cash and cash equivalent | 6,304 | 1,537 | 8,238 | 12,574 | |||
Receivables | 430 | 294 | 1,530 | 2,099 | |||
Inventory, net of allowances, customer advances and progress billings | 778 | 980 | |||||
Inventory | 778 | 980 | |||||
Other current assets | 498 | 553 | 747 | 2,509 | |||
Other undisclosed current assets | 525 | 499 | 353 | 1,025 | |||
Total current assets: | 8,534 | 3,863 | 10,868 | 18,207 | |||
Noncurrent Assets | |||||||
Operating lease, right-of-use asset | 307 | 546 | |||||
Nontrade receivables | 1,093 | 3,148 | |||||
Property, plant and equipment | 566 | 690 | 391 | ||||
Intangible assets, net (including goodwill) | 4,372 | 5,255 | |||||
Intangible assets, net (excluding goodwill) | 4,372 | 5,255 | |||||
Other noncurrent assets | 504 | ||||||
Total noncurrent assets: | 5,245 | 6,492 | 1,484 | 3,652 | |||
TOTAL ASSETS: | 13,779 | 10,355 | 12,352 | 21,859 | |||
LIABILITIES AND EQUITY | |||||||
Liabilities | |||||||
Current Liabilities | |||||||
Accounts payable and accrued liabilities, including: | 1,705 | 2,610 | 1,625 | 1,570 | |||
Accounts payable | 602 | 1,196 | |||||
Accrued liabilities | 607 | 777 | |||||
Other undisclosed accounts payable and accrued liabilities | 495 | 637 | 1,625 | 1,570 | |||
Deferred revenue | 2,487 | 2,338 | 2,837 | 2,099 | |||
Debt | 515 | 353 | |||||
Due to related parties | ✕ | ✕ | 13 | ||||
Other undisclosed current liabilities | 744 | 582 | 201 | ||||
Total current liabilities: | 5,451 | 5,884 | 4,663 | 3,683 | |||
Noncurrent Liabilities | |||||||
Long-term debt and lease obligation | 403 | ||||||
Long-term debt, excluding current maturities | 403 | ||||||
Liabilities, other than long-term debt | 81 | 356 | 1,093 | 3,148 | |||
Deferred revenue | 1,093 | 3,148 | |||||
Operating lease, liability | 81 | 356 | |||||
Other undisclosed noncurrent liabilities | 64 | 25 | 51 | 22 | |||
Total noncurrent liabilities: | 145 | 784 | 1,143 | 3,170 | |||
Total liabilities: | 5,596 | 6,668 | 5,806 | 6,853 | |||
Equity | |||||||
Equity, attributable to parent | 8,329 | 3,799 | 6,625 | 15,058 | |||
Preferred stock | 13 | ||||||
Common stock | 35 | 23 | 149 | 136 | |||
Treasury stock, value | (0) | (0) | |||||
Additional paid in capital | 60,972 | 46,159 | 38,440 | 38,440 | |||
Accumulated other comprehensive loss | (713) | (575) | (788) | (661) | |||
Accumulated deficit | (51,964) | (41,808) | (31,176) | (22,870) | |||
Equity, attributable to noncontrolling interest | (146) | (112) | (79) | (51) | |||
Total equity: | 8,183 | 3,687 | 6,546 | 15,007 | |||
TOTAL LIABILITIES AND EQUITY: | 13,779 | 10,355 | 12,352 | 21,859 |
Income Statement (P&L) ($ in thousands)
12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
---|---|---|---|---|---|---|
Revenues | 3,112 | 1,257 | 437 | 1,980 | ||
Cost of revenue | (1,686) | (930) | ||||
Cost of product and service sold | (70) | (190) | ||||
Other undisclosed gross profit | ||||||
Gross profit: | 1,426 | 327 | 437 | 1,980 | ||
Operating expenses | (12,134) | (13,660) | (8,774) | (7,554) | ||
Government assistance, operating income, increase (decrease) | ✕ | ✕ | ✕ | ✕ | ||
Other undisclosed operating income | 425 | 738 | ||||
Operating loss: | (10,283) | (12,595) | (8,337) | (5,573) | ||
Nonoperating income (expense) | 92 | 1,931 | 3 | (1,487) | ||
Investment income, nonoperating | (136) | |||||
Loss, foreign currency transaction, before tax | (1) | (10) | (4) | |||
Interest and debt expense | (167) | (224) | (8) | (1,094) | ||
Loss from continuing operations before equity method investments, income taxes: | (10,358) | (10,888) | (8,342) | (8,154) | ||
Other undisclosed income from continuing operations before income taxes | 1,094 | |||||
Loss from continuing operations: | (10,358) | (10,888) | (8,342) | (7,060) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (8,342) | (7,060) | |
Other undisclosed net income | 167 | 224 | 8 | |||
Net loss: | (10,191) | (10,665) | (8,334) | (7,060) | ||
Net income attributable to noncontrolling interest | 34 | 33 | 28 | 23 | ||
Net loss available to common stockholders, diluted: | (10,157) | (10,632) | (8,306) | (7,037) |
Comprehensive Income ($ in thousands)
12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
---|---|---|---|---|---|---|
Net loss: | (10,191) | (10,665) | (8,334) | (7,060) | ||
Other undisclosed comprehensive income (loss) | (137) | 213 | (127) | (297) | ||
Comprehensive loss: | (10,328) | (10,452) | (8,461) | (7,358) | ||
Comprehensive income, net of tax, attributable to noncontrolling interest | 34 | 33 | 28 | 23 | ||
Comprehensive loss, net of tax, attributable to parent: | (10,294) | (10,419) | (8,433) | (7,335) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.